Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension.
Journal: Respiratory medicine
Published: June 18, 2025
Objective clinical scoring system and diagnostic variability in idiopathic pulmonary fibrosis.
Journal: BMC pulmonary medicine
Published: October 24, 2024
Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: June 29, 2023
A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen.
Journal: Annals of the American Thoracic Society
Published: October 22, 2021
BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension.
Journal: Pulmonary circulation
Published: October 15, 2021
Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.
Journal: The Lancet. Respiratory medicine
Published: January 21, 2021
Showing 1-7 of 7
Last Updated: 09/26/2026